View
219
Download
1
Category
Tags:
Preview:
Citation preview
Data Entry
Table of Contents
• Overview• Database entry• Areas involved in Data Entry Function of Database• Sources of AEs and form of Data Received• Different ways of arrival of Data• Types of Data Entry
– Outsourcing for data entry– Head quarter data entry– Geographic data entry by region– Country data entry
• Data entry unit• Critical issues data entry• Data elements• Steps of data entry
Overview of Data Entry
• Any company that receives more than a handful of AEs, whether for marketed products or for products only in clinical trials, needs a database to collect, assemble, and report on these AEs.
• It is necessary to have an AE database that allows, a minimum, either easy data entry manually and by E2B or a customized upload, preparation, and printing of MedWatch and CIOMS.
Database Entry
• At this point, the case should be entered into the computerized safety database.
• If case is received electronically, should be reviewed in “holding area” before uploading into the safety database and tested for trusted source
• Manual data entry should be done for cases that arrive manually using a standard data collection form
Sources of manual data
Case report formHandwritten notes
CIOMS I/Med Watch formsHospital recordsPhysicians’ notesTelephone reports
Database Entry Continue..
• Companies have initial review by a medical professional who highlights terms for data entry Other companies send source documents directly to data entry group and perform reviews later
• If a case number (control number/medical reference number) has not been assigned at triage, it is done now
• MedDRA coding of AEs, medical histories and drug coding is done by drug safety group or dedicated coding group
• Case narrative is written. Narratives should be written in a standard way in terms of format, content, follow up information, etc.
• Narrative is the key summary of the case and should be a good “stand-alone” summary of a case
Areas involved in Data Entry Function of Database
• Upload capabilities from other databases or via E2B.• Tabular entry of laboratory data as well as manual entry.• Multiple narratives for the same case.• Ability to handle multiple labels.• Ability to handle one or more reporter for a single case.• Tracking of information in and out.• Duplicate check for cases using multiples.• Ability to add fields as needed.• Ability to close/complete a case and reopen it as needed.• Edit checks.• Spell check in multiple languages.• Ability to handle combination drugs, drug devices, OTC, and so forth.
Sources of AEs and form of Data Received
There are different types of sources, such as; Solicited sources (solicited reports are those derived from organized data
collection systems such as clinical trials, registries, post-approval patient use programs, other patient support, disease management programs, surveys of patients or healthcare providers, or information gathering on efficacy or patient compliance). These kind of sources are not considered spontaneous.
Unsolicited sources (also called spontaneous reports) ( a spontaneous report is an unsolicited communication by a healthcare professional, or consumer to a company, regulatory authority or other organizations that describes one or more adverse drug reactions in a patient who was given one or more medicinal products and that does not derive from a study or any organized data collection.
Different ways of arrival of Data
There are so many a data or a report can arrive to a company- Cases can be received from primary sources like patient, healthcare professional,
consumers or lawyers. Another source of case is from literature reports published in magazines, journals
etc. It can also be received from health agencies by means of MedWatch forms,
CIOMS-1 form, VAERS form. Other sources are clinical studies, spontaneous reports, stimulated reports, legal
cases. The above sources can be received via phone, fax, email, website, reports to sales
representative etc.
Types of Data Entry
• Companies make strategic, organizational, and operational decisions on where data entry should occur, esp. if they are multinational companies. This streamlines operations and allows for standardization across all data entry personnel and for backup data entry if one site should go out of service so companies respond to these needs in multiple ways:– Headquarter data entry – for small companies or AEs from only one or two
countries, it is sometimes feasible to ship all AEs to the main drug safety dept for data entry.
– Geographic data entry – one (or sometimes two) regional data entry center each for North America, Europe, South America, and Asia/Africa. Follow up of cases is done locally in the local language and the data transmitted to the regional data center for entry into the corporate safety database.
– Country data entry – some companies have more dispersed entry than by region. They may designate major affiliates or subsidiaries, particularly those with high volumes of AEs, to do data entry for their country.
Outsourcing for data entry • Sometimes Companies may hire CROs to do data entry for them, shipping
completed cases for review back to the company.
• This could occur for all cases or only for those cases in a country where the company chooses not to set up a data entry function.
• Some countries handle clinical trial data entry separately from post marketing data entry even if the data goes into the same safety database.
Types of Data Entry
Critical Issues: Data Entry
• Maintaining standards and consistency across multiple and diverse data entry sites, often speaking different languages and working under different conditions and time zones is always challenging.
• Organizational reporting may also present issues if the safety personnel abroad report only locally and not “dotted line” or directly to the head safety office.
• Training is harder over greater distances even with online and other high-tech training tools.
• Time zones interfere with workflow.• Quality is harder to measure and maintain.• IT issues occur in terms of storage, networks, security, data transmission speed, and
support.
Steps of Data Entry
Company receive Adverse events cases and data is being entered into drug safety database • Inbox screen• Summary Screen• Case ID screen• Patient screen • Medical History Screen• Drug History Screen• Reaction Screen• Drug Screen• Reporter Screen• Narrative Screen• Diagnostic Screen• Processing Functions Screen
Inbox Screen
Owner AER# Suspect product
Country of origin
Reported Reaction
Serious? Received Date
Priority
This screen usually has a list of the AEs, with the date received, level of seriousness and the level of priority.
Summary Screen-
AER XYZ Version 0 Owner : A Queue: case processing step
Summary
Case ID
Patient
MedHx
DrugHx
Reaction
Drug Reporter
Narrative
Diagnostic
Processing Fx
This screen usually has the summary of an individual’s case pertaining to his reporter, patient info, med, drug and reaction
Qtech- Sol Professional Development Center, NJ, USA.
15
Case IdentificationReport TypeLiteraturePrimary AuthorCitation: Author 1, Author 2, Title of article, Title of journal, Issue date, Volume number, Page numbers SeriousnessMedically ConfirmedClassificationCase CharacteristicDate 0 version receivedLatest information received dateLocal Case ID Study Protocol numberInvestigator numberCenter number
Medication number
CRF number ReporterPatientMedical HistoryDrug HistoryReactionDrugNarrativeDiagnostic
Summary Screen
Case ID
Adverse event
Pregnancy
Product complaint
Literature
Parent/Child
Invalid case
Serious Non-Serious Seriousness not determined
Life threatening Caused/Prolonged hospitalization
Disability/Incapacity
Death Congenital Anomaly/ Birth Defect
Other Medically Important Condition
•Initiating company unit•Country of primary source•Country where AE occurred•Local case ID •Case Priority•Version Dates •Version initially received •Received by case processing center•Report Type •Classification•Nature of complaint•Case Characteristic •Received by local safety unit •Medically confirmed Yes No•Regulatory relevant update Yes No•Seriousness•Other Identification numbers
Patient screen
Patient IDPatient SexDate of BirthAgeAge groupHeightWeightDate of last menstrual periodPhysician aware of adverse event Yes
No UnknownPermission to contact PhysicianYes NoUnknown DeathDate of DeathWas Autopsy done?Date of Autopsy
Patient NumbersGeneral Practioner Record numberMedical Specialist Record numberHospital Record number Social HistoryNumbers of cigarettes per dayNumber of years smokedNumbers of drinks per dayType of alcohol Physical activity Patient other history Pregnancy Previous pregnanciesCurrent pregnancyExpected date of deliveryDid mother experienced any medical problemsAny relevant information from fatherCurrent pregnancy outcomesClinical status of pregnancyClinical condition of fetus
Medical history screen
• Reported Diseases/Surgical Procedures: • Low level term : • Preferred term :
• Start date :• End date :• Comments :
Drug History Screen
• Reported Drug Name: • Generic drug name: Quitex • Start date:12 Jan 2011• End Date:• Route of administration: Oral• • Reported Indication: Hypothyroidism • Coding• Low level term: ____________________________• Preferred term: ____________________________• •
Reaction Screen
Reported Reaction: Pulmonary embolism
Coding
Low level term: ____________________________
Preferred term: ____________________________
Serious: Yes No
Outcome:
Recovered
Not Recovered
Recovering
Fatal
Unknown
Date Reaction Started: 16 Jan 2011
Date Reaction Ended: 19 Jan 2011
Reaction Duration:
Drug Screen
Made by: Company drug Non-company drug
Coding
Reported drug name: SUSPECT DRUG BRAND NAME
Generic Drug Name: GENERIC NAME: Quitex
Characterization: Suspect Suspect Drug InteractingConcomitant
Action taken with drug: Discontinued
Dose formulation:
Rout of administration: Oral
Drug treatment duration
Dose:5mg
Frequency
Unit
Drug start date:12Jan2011
Drug end date:
First reaction occurred with drug:Pulmonary embolism
•
Drug Indication: _____________________
Coding
Low level term: _____________________
Preferred term:_____________________
Batch numbers
Rank
Lot number
Expiration date:
Product Complaint number
Date sent to QA
Investigation Result
Description
Reporter Screen
•Qualification•Title•Given Name•Middle Name•Family Name•Degree•Address•Department•Organization•Contact information•Company representative information•Due-diligence Request
Narrative Screen
Upon completion of all the data entry narratives are drafted.
AER 000XYZ Version 0 Owner: Paul K. Queue: Case Processing StepSummary Case
IDPatient Medi
cal Histor
y
Drug History
Reaction
Drug Reporter Narrative Diagnostic Processing Function
• Finally, a safety database is both a core element of any Pharmacovigilance system and a legal pre-requisite for pharmaceutical companies, wishing to place a medicine or medicinal product onto any EU market as per E2B.
These companies will and still need to strive in entering the accurate data with the system over the years .
Summary
Recommended